Portal de Periódicos da CAPES

Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study

2019; SAGE Publishing; Volume: 24; Issue: 2 Linguagem: Inglês

10.1177/1087054719864644

1557-1246

Sharon B. Wigal, Seth C. Hopkins, Kenneth S. Koblan, Ann Childress, Justine Kent, Joyce Tsai, Jay Hsu, Antony Loebel, Robert Goldman,

Child and Adolescent Psychosocial and Emotional Development

Objective: To evaluate the efficacy and safety of dasotraline for treatment of ADHD in children. Method: Children (ages 6-12 years; N = 112) with ADHD were randomized, double-blind, to 14 days of once-daily evening doses of dasotraline 4 mg or placebo. ADHD symptom severity was measured at baseline and Day 15 in seven, 30-min classroom sessions using the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) and the Permanent Product Measure of Performance (PERMP) math test. Results: Significant improvement was observed for dasotraline versus placebo in the SKAMP-combined score (−3.2 vs. +2.0; p < .001; effect size = 0.85) and SKAMP and PERMP subscale scores. The three most common adverse events for dasotraline (vs. placebo) were insomnia (19.6% vs. 3.6%), headache (10.7% vs. 8.9%), and decreased appetite (10.7% vs. 3.6%). Conclusion: In this laboratory classroom study, dasotraline 4 mg was found to be an efficacious and generally well-tolerated treatment for ADHD in children aged 6 to 12 years.